Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
ANIP vs AMRX vs TEVA vs VTRS vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
ANIP vs AMRX vs TEVA vs VTRS vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.78B | $4.31B | $41.93B | $20.25B | $1.61B |
| Revenue (TTM) | $883M | $3.02B | $17.35B | $14.56B | $4.18B |
| Net Income (TTM) | $78M | $72M | $1.56B | $-296M | $-1.82B |
| Gross Margin | 69.1% | 36.9% | 52.1% | 34.4% | 34.2% |
| Operating Margin | 12.6% | -0.2% | 13.2% | 1.0% | -4.1% |
| Forward P/E | 9.2x | 13.8x | 14.5x | 7.1x | 5.6x |
| Total Debt | $325M | $124M | $17.38B | $14.70B | $3.97B |
| Cash & Equiv. | $286M | $282M | $3.56B | $1.35B | $532M |
ANIP vs AMRX vs TEVA vs VTRS vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ANI Pharmaceuticals… (ANIP) | 100 | 270.2 | +170.2% |
| Amneal Pharmaceutic… (AMRX) | 100 | 281.7 | +181.7% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
| Viatris Inc. (VTRS) | 100 | 101.9 | +1.9% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANIP vs AMRX vs TEVA vs VTRS vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANIP carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 43.8%, EPS growth 419.2%, 3Y rev CAGR 40.8%
- Lower volatility, beta 0.63, Low D/E 60.1%, current ratio 2.71x
- Beta 0.63, yield 0.1%, current ratio 2.71x
- 43.8% revenue growth vs VTRS's -3.0%
Among these 5 stocks, AMRX doesn't own a clear edge in any measured category.
TEVA ranks third and is worth considering specifically for long-term compounding.
- -28.3% 10Y total return vs ANIP's 84.7%
- 9.0% margin vs PRGO's -43.5%
VTRS is the clearest fit if your priority is momentum.
- +107.8% vs PRGO's -51.2%
PRGO is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower P/E (5.6x vs 7.1x)
- 9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 43.8% revenue growth vs VTRS's -3.0% | |
| Value | Lower P/E (5.6x vs 7.1x) | |
| Quality / Margins | 9.0% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.63 vs PRGO's 1.18, lower leverage | |
| Dividends | 9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +107.8% vs PRGO's -51.2% | |
| Efficiency (ROA) | 5.4% ROA vs PRGO's -19.8%, ROIC 11.2% vs 3.7% |
ANIP vs AMRX vs TEVA vs VTRS vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ANIP vs AMRX vs TEVA vs VTRS vs PRGO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PRGO leads in 2 of 6 categories
ANIP leads 1 • AMRX leads 1 • TEVA leads 0 • VTRS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ANIP leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 19.6x ANIP's $883M. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ANIP holds the edge at +29.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $883M | $3.0B | $17.3B | $14.6B | $4.2B |
| EBITDAEarnings before interest/tax | $203M | $169M | $3.3B | $2.3B | $58M |
| Net IncomeAfter-tax profit | $78M | $72M | $1.6B | -$296M | -$1.8B |
| Free Cash FlowCash after capex | $128M | $150M | $1.2B | $1.7B | $108M |
| Gross MarginGross profit ÷ Revenue | +69.1% | +36.9% | +52.1% | +34.4% | +34.2% |
| Operating MarginEBIT ÷ Revenue | +12.6% | -0.2% | +13.2% | +1.0% | -4.1% |
| Net MarginNet income ÷ Revenue | +8.9% | +2.4% | +9.0% | -2.0% | -43.5% |
| FCF MarginFCF ÷ Revenue | +14.5% | +5.0% | +6.8% | +11.7% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.6% | +11.5% | +2.3% | +8.1% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +2.1% | +72.2% | +105.9% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 25.3x trailing earnings, ANIP trades at a 59% valuation discount to AMRX's 62.4x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than VTRS's 248.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.8B | $4.3B | $41.9B | $20.2B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $1.8B | $4.2B | $55.8B | $33.6B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 25.27x | 62.36x | 30.01x | -5.80x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.25x | 13.81x | 14.55x | 7.12x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 8.99x | — | 17.65x | 248.54x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 2.02x | 1.43x | 2.43x | 1.42x | 0.38x |
| Price / BookPrice ÷ Book value/share | 3.29x | 4.62x | 5.34x | 1.38x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 9.62x | 15.98x | 36.52x | 10.45x | 11.12x |
Profitability & Efficiency
AMRX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-51 for PRGO. AMRX carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), AMRX scores 8/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +14.5% | +7.5% | +20.7% | -2.0% | -50.7% |
| ROA (TTM)Return on assets | +5.4% | +2.0% | +3.9% | -0.8% | -19.8% |
| ROICReturn on invested capital | +11.2% | -0.2% | +7.7% | -6.6% | +3.7% |
| ROCEReturn on capital employed | +9.9% | -0.2% | +8.0% | -8.1% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 8 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.60x | 0.13x | 2.20x | 1.00x | 1.35x |
| Net DebtTotal debt minus cash | $40M | -$158M | $13.8B | $13.4B | $3.4B |
| Cash & Equiv.Liquid assets | $286M | $282M | $3.6B | $1.3B | $532M |
| Total DebtShort + long-term debt | $325M | $124M | $17.4B | $14.7B | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.82x | 2.09x | 2.51x | -0.51x | -7.20x |
Total Returns (Dividends Reinvested)
Evenly matched — AMRX and VTRS each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, VTRS leads with a +107.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors AMRX at 89.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +7.0% | +8.4% | +16.3% | +40.5% | -13.5% |
| 1-Year ReturnPast 12 months | +18.5% | +90.0% | +104.6% | +107.8% | -51.2% |
| 3-Year ReturnCumulative with dividends | +97.1% | +579.2% | +297.5% | +91.8% | -58.1% |
| 5-Year ReturnCumulative with dividends | +117.4% | +163.8% | +246.2% | +40.3% | -60.1% |
| 10-Year ReturnCumulative with dividends | +84.7% | -54.9% | -28.3% | -51.5% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +25.4% | +89.4% | +58.4% | +24.2% | -25.2% |
Risk & Volatility
Evenly matched — ANIP and VTRS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ANIP is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTRS currently trades 99.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.63x | 1.17x | 1.13x | 0.99x | 1.18x |
| 52-Week HighHighest price in past year | $99.50 | $15.20 | $37.35 | $17.45 | $28.44 |
| 52-Week LowLowest price in past year | $56.71 | $7.02 | $14.99 | $8.19 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +84.3% | +90.3% | +96.4% | +99.7% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 64.4 | 62.7 | 73.5 | 75.7 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 328K | 1.7M | 6.6M | 10.6M | 3.4M |
Analyst Outlook
PRGO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ANIP as "Buy", AMRX as "Buy", TEVA as "Buy", VTRS as "Hold", PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs -12.3% for VTRS (target: $15). For income investors, PRGO offers the higher dividend yield at 9.81% vs VTRS's 2.76%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $124.00 | $17.00 | $39.00 | $15.25 | $20.00 |
| # AnalystsCovering analysts | 10 | 16 | 46 | 12 | 36 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | +2.8% | +9.8% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 1 | 0 | 10 |
| Dividend / ShareAnnual DPS | $0.05 | — | — | $0.48 | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | 0.0% | +2.5% | 0.0% |
PRGO leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). ANIP leads in 1 (Income & Cash Flow). 2 tied.
ANIP vs AMRX vs TEVA vs VTRS vs PRGO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ANIP or AMRX or TEVA or VTRS or PRGO a better buy right now?
For growth investors, ANI Pharmaceuticals, Inc.
(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ANIP or AMRX or TEVA or VTRS or PRGO?
On trailing P/E, ANI Pharmaceuticals, Inc.
(ANIP) is the cheapest at 25. 3x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ANIP or AMRX or TEVA or VTRS or PRGO?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: ANIP returned +84. 7% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ANIP or AMRX or TEVA or VTRS or PRGO?
By beta (market sensitivity over 5 years), ANI Pharmaceuticals, Inc.
(ANIP) is the lower-risk stock at 0. 63β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 88% more volatile than ANIP relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — ANIP or AMRX or TEVA or VTRS or PRGO?
By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.
(ANIP) is pulling ahead at 43. 8% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ANIP or AMRX or TEVA or VTRS or PRGO?
ANI Pharmaceuticals, Inc.
(ANIP) is the more profitable company, earning 8. 9% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — ANIP leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ANIP or AMRX or TEVA or VTRS or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — ANIP or AMRX or TEVA or VTRS or PRGO?
In this comparison, PRGO (9.
8% yield), VTRS (2. 8% yield) pay a dividend. ANIP, AMRX, TEVA do not pay a meaningful dividend and should not be held primarily for income.
09Is ANIP or AMRX or TEVA or VTRS or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Viatris Inc.
(VTRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 2. 8% yield). Both have compounded well over 10 years (VTRS: -51. 5%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ANIP and AMRX and TEVA and VTRS and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ANIP is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock; TEVA is a mid-cap quality compounder stock; VTRS is a mid-cap quality compounder stock; PRGO is a small-cap income-oriented stock. VTRS, PRGO pay a dividend while ANIP, AMRX, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.